BR112019017018A2 - formulações de canabinoides para o tratamento de dermatite e doenças de pele inflamatórias - Google Patents

formulações de canabinoides para o tratamento de dermatite e doenças de pele inflamatórias Download PDF

Info

Publication number
BR112019017018A2
BR112019017018A2 BR112019017018A BR112019017018A BR112019017018A2 BR 112019017018 A2 BR112019017018 A2 BR 112019017018A2 BR 112019017018 A BR112019017018 A BR 112019017018A BR 112019017018 A BR112019017018 A BR 112019017018A BR 112019017018 A2 BR112019017018 A2 BR 112019017018A2
Authority
BR
Brazil
Prior art keywords
skin
cbd
pharmaceutical composition
alcohol
fact
Prior art date
Application number
BR112019017018A
Other languages
English (en)
Portuguese (pt)
Inventor
Cooper Eugene
callahan Matthew
Original Assignee
Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900495A external-priority patent/AU2017900495A0/en
Application filed by Botanix Pharmaceuticals Ltd, Botanix Pharmaceuticals Inc filed Critical Botanix Pharmaceuticals Ltd
Priority claimed from PCT/AU2018/050044 external-priority patent/WO2018148785A1/en
Publication of BR112019017018A2 publication Critical patent/BR112019017018A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015Drug-containing film-forming compositions, e.g. spray-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112019017018A 2017-02-15 2018-01-24 formulações de canabinoides para o tratamento de dermatite e doenças de pele inflamatórias BR112019017018A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459363P 2017-02-15 2017-02-15
AU2017900495A AU2017900495A0 (en) 2017-02-15 Formulations of Cannabinoids for the Treatment of Dermatitis and Inflammatory Skin Diseases
PCT/AU2018/050044 WO2018148785A1 (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases

Publications (1)

Publication Number Publication Date
BR112019017018A2 true BR112019017018A2 (pt) 2020-04-14

Family

ID=67766794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019017018A BR112019017018A2 (pt) 2017-02-15 2018-01-24 formulações de canabinoides para o tratamento de dermatite e doenças de pele inflamatórias

Country Status (8)

Country Link
US (1) US20210401768A1 (enExample)
EP (1) EP3582768A4 (enExample)
JP (2) JP7012089B2 (enExample)
CN (1) CN110545807B (enExample)
AU (1) AU2018221880B2 (enExample)
BR (1) BR112019017018A2 (enExample)
CA (1) CA3053500A1 (enExample)
IL (1) IL268720B2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020508992A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド ざ瘡の処置のためのカンナビノイドの製剤
BR112020014911A2 (pt) 2018-01-24 2020-12-08 Botanix Pharmaceuticals Ltd Regime de dosagem de canabinoide para dermatite e condições de pele inflamatórias
CN111000740A (zh) * 2020-01-07 2020-04-14 杭州百芮生物科技有限公司 一种添加大麻提取成分组合物、制备方法及其应用
CN111671885A (zh) * 2020-06-15 2020-09-18 中国人民解放军西部战区总医院 一种用于治疗放射性皮炎的药物
CN111514280A (zh) * 2020-06-15 2020-08-11 中国人民解放军西部战区总医院 一种预防放射性皮炎的药物
CN113479456A (zh) * 2021-04-06 2021-10-08 上海思乐得不锈钢制品有限公司 一种用于储运生物制品的真空容器
US20230039887A1 (en) * 2021-07-20 2023-02-09 Enveric Biosciences, Inc. Compositions for topical treatment of radiation dermatitis
US12059393B2 (en) 2022-02-11 2024-08-13 Akos Biosciences, Inc. Compositions for topical treatment of radiation dermatitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104268D0 (en) * 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
ES2312643T5 (es) * 2001-07-18 2011-10-18 Unilever N.V. Composiciones para el tratamiento del cabello y/o del cuero cabelludo.
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
EP2444081B1 (en) * 2010-10-19 2015-04-08 Parenteral, A.S. A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
GB201019240D0 (en) * 2010-11-15 2010-12-29 Vib Vzw Respiratory syncytical virus vaccine
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
EP2664327A1 (en) * 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
NZ707855A (en) * 2012-11-06 2018-11-30 Rochal Ind Llc Delivery of biologically-active agents using volatile, hydrophobic solvents
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
EP3265081A4 (en) * 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
HK1254812A1 (zh) * 2015-06-23 2019-07-26 APIRx Pharmaceuticals, LLC 包含大麻素的抗微生物组合物

Also Published As

Publication number Publication date
AU2018221880B2 (en) 2023-08-17
JP2020508994A (ja) 2020-03-26
IL268720A (en) 2019-10-31
CN110545807B (zh) 2022-11-22
EP3582768A4 (en) 2020-11-18
AU2018221880A1 (en) 2019-09-05
IL268720B2 (en) 2024-09-01
JP7012089B2 (ja) 2022-01-27
CN110545807A (zh) 2019-12-06
JP2022050641A (ja) 2022-03-30
US20210401768A1 (en) 2021-12-30
CA3053500A1 (en) 2018-08-23
IL268720B1 (en) 2024-05-01
EP3582768A1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
BR112019017018A2 (pt) formulações de canabinoides para o tratamento de dermatite e doenças de pele inflamatórias
JP7559173B2 (ja) 皮膚炎および炎症性皮膚状態のためのカンナビノイド投薬レジメン
BR112019017049A2 (pt) formulações de canabinoides para o tratamento de acne
WO2018148785A1 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
WO2018148787A1 (en) Formulations of cannabinoids for the treatment of psoriasis
JP7561252B2 (ja) ざ瘡のためのカンナビノイド投薬レジメン
Salau et al. Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats
WO2018148786A1 (en) Formulations of cannabinoids for the treatment of acne
BR112019017011A2 (pt) formulações de canabinoides para o tratamento de psoríase
RU2440108C2 (ru) Фармацевтическая композиция для лечения аллергических и воспалительных заболеваний кожи
BR112019017045A2 (pt) composições para tratar acne

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2654 DE 16-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.